Published Research Summaries (click "Search" in Menu to filter)

Real-world data: Medical Cannabis is effective & safe for many conditions

Study Objective: To investigate the safety and effectiveness of medical cannabis (MC) in the real-world clinical practice setting.

Study: CBD doses over 300mg per day are medically more effective

This study reviewed evidence of the effectiveness and safety of oral CBD at doses below 400mg. It was published in October 2022 in the journal Clinical and Translational Science.

Treatment-resistant fibromyalgia symptoms improve with cannabis

This study focused on women with treatment-resistant fibromyalgia to determine if cannabis treatment could improve their quality of life. It was published in the official journal of the World Institute of Pain, Pain Practice in February 2023.

Cannabis & chronic neuropathic pain (review study)

Eight randomized controlled trials were included in the analysis. Six showed significant improvement in sleep quality and eight showed a significant reduction in pain scores.

Chronic pain and cannabis: helps reduce other pain medications

This study collected and analyzed patient information on their use of cannabis for chronic non-cancer pain. The research letter was published in January 2023 on the Journal of the American Medical Association (JAMA) Network.

Cannabis use does not predispose users to high blood pressure

This study retrospectively evaluated data collected by the National (US) Health and Nutrition Examination Survey from 2017 to 2018. It examined the relationship between past cannabis use and hypertension (high blood pressure). It was published in December 2022 in The Journal of Clinical Hypertension.

New study reinforces positive results for cannabis use and Multiple Sclerosis

Published in the International Journal of MS Care in December 2022, this study examined medical cannabis (MC) as part of a comprehensive treatment plan for patients with Multiple Sclerosis (MS).

CBD isolate helps young patients with Treatment Resistant Epilepsy

This study was published in December 2022 in the journal Epilepsia. It examined CBD isolate as an add-on treatment in patients suffering from treatment resistant epilespy (TRE). For the patients that completed the study, their seizures were reduced by about one-half to two-thirds over a period of almost 2 years.

Study: Cannabis helps some with headaches

The data was collected from 200 patients in a tertiary headache clinic in Alberta, Canada. They tracked the headache diagnosis and frequency, the doses and methods of cannabinoid delivery, patient benefits, and adverse effects.

Cannabinoids and Terpenes tested for their effects on inflammation

The results showed that the cannabinoids worked much better than terpenes, and that THC showed the greatest immune modulating activity of all molecules tested. CBDV and CBG followed THC, while CBD ranked last in their experiments.

THC and CBD seem to help heal wounds and slow skin aging

This study examined the effects of THC and CBD on human skin models to determine if they could assist in wound healing, and slow the process of skin cell aging. It was published in December 2022 in the journal Cells.

THC recommended as a cardioprotective drug for some conditions

This research was conducted to determine if THC might have protective effects in the treatment of cardiovascular system dysfunction arising from Ischemia / Reperfusion (IR). IR is loss of blood flow, then the return of blood flow to the heart - both conditions can create damage or injury.

Full spectrum cannabis extract shown to kill Ovarian Cancer cells

This in vitro (in a lab) study examined the effects of different cannabinoid combinations of ovarian cancer cell models. It was published in the journal Molecules in October 2022. One mixture was 50 times more cytotoxic to cancer cells than to normal cells.